Keyphrases
Hachimijiogan
100%
Mild Alzheimer's Disease
100%
Randomized multicenter Trial
100%
Acetylcholinesterase Inhibitors (AChEI)
62%
Confidence Interval
50%
Change from Baseline
37%
Instrumental Activities of Daily Living
25%
Apathy Scale
25%
Q-score
25%
Neuropsychiatric Inventory Questionnaire (NPI-Q)
25%
Japanese Version
12%
Traditional Japanese Medicine
12%
Japan
12%
No Significant Difference
12%
Clinical Trials
12%
Treatment Initiation
12%
Subgroup Analysis
12%
Mini-Mental State Examination
12%
Dementia
12%
Alzheimer's Disease
12%
Cognitive Dysfunction
12%
Kampo
12%
Clinical Trial Registry
12%
Novel Treatments
12%
Progressive Neurodegeneration
12%
Adjuvant Effect
12%
Cognitive Component
12%
Alzheimer's Disease Assessment Scale
12%
Medicine and Dentistry
Alzheimer's Disease
100%
Hachimijiogan
100%
Acetylcholinesterase Inhibitor
62%
Clinical Trial
25%
Neuropsychiatric Inventory
25%
Cognitive Defect
12%
Disease
12%
Subgroup Analysis
12%
Deterioration
12%
Kampo
12%
Adjuvant Therapy
12%
Neurodegeneration
12%
Mini-Mental State Examination
12%
Alzheimer Disease Assessment Scale
12%
Homeopathy
12%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
100%
Hachimijiogan
100%
Cholinesterase Inhibitor
62%
Clinical Trial
25%
Kampo Medicine (Drug)
12%
Disease
12%
Nerve Degeneration
12%
Deterioration
12%
Cognitive Defect
12%
Neuroscience
Alzheimer's Disease
100%
Hachimijiogan
100%
Acetylcholinesterase Inhibitor
62%
Cognitive Disorders
12%
Neurodegeneration
12%
Kampo Medicine (Drug)
12%
Adjuvant Therapy
12%